Exploring Evolving Antiplatelet Paradigms in Acute Myocardial Infarction

Program Description

This educational activity aims to provide cardiology professionals with critical insight into evolving antiplatelet paradigms for managing AMI. Through an interactive, case-based format, participants explore the clinical profiles of current and emerging antiplatelet therapies (e.g., P2Y12 inhibitors, GP IIb/IIIa inhibitors), evaluate available evidence surrounding pretreatment strategies, and assess the applicability of dual anti-platelet therapy (DAPT) de-escalation approaches. Expert faculty guide learners in applying evidence-based strategies to clinical scenarios, enabling them to make informed decisions that balance ischemic and bleeding risks in AMI care.This educational activity aims to provide cardiology professionals with critical insight into evolving antiplatelet paradigms for managing AMI. Through an interactive, case-based format, participants explore the clinical profiles of current and emerging antiplatelet therapies (e.g., P2Y12 inhibitors, GP IIb/IIIa inhibitors), evaluate available evidence surrounding pretreatment strategies, and assess the applicability of dual anti-platelet therapy (DAPT) de-escalation approaches. Expert faculty guide learners in applying evidence-based strategies to clinical scenarios, enabling them to make informed decisions that balance ischemic and bleeding risks in AMI care.

Target Audience

The target audience for this activity includes cardiologists, interventional cardiologists, emergency medicine specialists, interventional radiologists as well as advanced practice professionals and pharmacists working across these specialties.

Learning Objectives

Upon completion of this activity, the learner should be able to:

  • Differentiate the clinical profiles of antiplatelet agents (e.g., P2Y inhibitors, GP IIb/IIIa inhibitors) to inform evidence-based treatment selection in ACS management.
  • Assess the rationale supporting and opposing pretreatment in ACS to determine its clinical relevance and applicability in patient care.
  • Analyze the mechanisms efficacy, safety, and therapeutic potential of emerging pretreatment agents in late-stage development to prepare clinicians for their potential integration into ACS care, if approved in the future.
  • Evaluate DAPT de-escalation strategies for eligible patients by balancing ischemic protection with bleeding risks to reduce treatment burden.
Course summary
Available credit: 
  • 1.00 AAPA Category I CME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
08/21/2025
Course expires: 
08/21/2026
Cost:
$0.00
Rating: 
0
   Christopher Cannon, MD (moderator)
   Preventive Cardiology Section, Brigham and Women’s Hospital
   Professor of Medicine, Harvard Medical School
   Boston, MA
 
 
 
 
 
   Deepak L. Bhatt, MD, MPH, MBA
   Director of Mount Sinai Fuster Heart Hospital
   Dr. Valentin Fuster Professor of Cardiovascular Medicine
   Icahn School of Medicine at Mount Sinai
   New York, NY
 
   Dominick J. Angiolillo, MD, PhD
   Professor of Medicine
   Chief, Division of Cardiology
   Medical Director, UF Health Cardiovascular Center
   Director, Cardiovascular Research
   Program Director, Interventional Cardiology Fellowship
   University of Florida College of Medicine-Jacksonville
   Jacksonville, FL

This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.

image               image     

Joint Accreditation Statement

image

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

PHYSICIAN CREDIT
Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
NURSING CREDIT
Medical Education Resources designates this enduring material for a maximum of 1.0 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.
 
PHYSICIAN ASSOCIATES CREDIT 
Medical Education Resources has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME Credits. Physician Associates should only claim credit commensurate with the extent of their participation.

 

PHARMACISTS (ACPE)
Medical Education Resources designates this enduring continuing education for 1.0 hours (.01 CEUs) of the Accreditation Council for Pharmacy Education. This activity is certified as Knowledge based CPE.

Universal Program Number: JA0003680-9999-25-191-H01-P

CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.
Universal Program Number:
 

Staff Disclosures

Efficient LLC and Medical Education Resources' planners and managers have no financial relationships to disclose.

Faculty Disclosures

Dr. Cannon has the following financial relationships to disclose:

  • Advisory Boards: Amgen; Amryt/Chiesi: Ascendia: Biogen; BI; BMS; CSL Behring; Genomadix; Lilly; Janssen; Lexicon; Milestone; Novartis; Pfizer; and Rhoshan 
  • Research Grants: Amgen; Better Therapeutics; Boehringer-Ingelheim (BI); Novo Nordisk; and salary support from Colorado Prevention Center (CPC) Clinical Research, which gets research grant support from Amgen; Bayer; Cleerly; Esperion; Lexicon; and Silence

 Dr. Bhatt has the following financial relationships to disclose:

  • Advisory Boards: Angiowave; Antlia Bioscience; Bayer; Boehringer Ingelheim; CellProthera; Cereno Scientific; E-Star Biotech; High Enroll; Janssen; Level Ex; McKinsey; Medscape Cardiology; Merck; NirvaMed; Novo Nordisk; Repair Biotechnologies; Stasys; and Tourmaline Bio 
  • Board of Directors and Stock: American Heart Association New York City; Angiowave (stock options); Bristol Myers Squibb (stock); DRS.LINQ (stock options); and High Enroll (stock)
  • Consultant: Alnylam; Altimmune; Broadview Ventures; Corcept Therapeutics; Corsera; GlaxoSmithKline; Hims; SERB; SFJ; Summa Therapeutics; and Worldwide Clinical Trials 
  • Data Monitoring Committees: Acesion Pharma; Assistance Publique-Hôpitaux de Paris; Baim Institute for Clinical Research; Boston Scientific (Chair, PEITHO trial); Cleveland Clinic; Contego Medical (Chair, PERFORMANCE 2); Duke Clinical Research Institute; Mayo Clinic; Mount Sinai School of Medicine (for the ABILITY-DM trial, funded by Concept Medical for ALLAY-HF, funded by Alleviant Medical); Novartis; Population Health Research Institute; and Rutgers University (for the NIH-funded MINT Trial)
  • Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee); Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation); Baim Institute for Clinical Research (AEGIS-II executive committee funded by CSL Behring); Belvoir Publications (Editor in Chief, Harvard Heart Letter); Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees); CSL Behring (AHA lecture); Duke Clinical Research Institute; Engage Health Media; HMP Global (Editor in Chief; Journal of Invasive Cardiology); Medtelligence/ReachMD (CME steering committees); MJH Life Sciences; Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology); Philips (Becker's Webinar on AI)l; Population Health Research Institute; WebMD (CME steering committees); Wiley (steering committee)
  • Other: Clinical Cardiology (Deputy Editor) and Progress in Cardiovascular Diseases (Deputy Editor)
  • Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent)
  • Research Funding: Abbott; Acesion Pharm; Afimmune; Alnylam; Amarin; Amgen; AstraZeneca; Atricure; Bayer; Boehringer Ingelheim; Boston Scientific; CellProthera; Cereno Scientific; Chiesi; Cleerly; CSL Behring; Faraday Pharmaceuticals; Fractyl, Idorsia; Jansse; Javelin; Lexicon; Lilly; Medtronic; Merck; MiRUS; Moderna; Novartis; Novo Nordisk; Pfizer; PhaseBio; Regeneron; Reid Hoffman Foundation; Roche; Sanofi; Stasys; and 89Bio
  • Royalties: Elsevier (Editor, Braunwald’s Heart Disease)
  • Site Co-Investigator: Cleerly 

Dr. Angiolillo has the following Financial Relationship to disclose:

  • Consultant: Abbott; Amgen; Anthos; AstraZeneca; Bayer; Biosensors; Boehringer Ingelheim; Bristol-Myers Squibb; Chiesi; CSL Behring; Daiichi-Sankyo; Eli Lilly; Faraday; Haemonetics; Janssen; Merck; Novartis; Novo Nordisk; PhaseBio; PLx Pharma; Pfizer; Sanofi; and Vectura 
  • Institution Research Grants: Amgen; AstraZeneca; Bayer; Biosensors; CeloNova; CSL Behring; Daiichi-Sankyo; Eisai; Eli Lilly; Faraday; Gilead; Idorsia; Janssen; Matsutani Chemical Industry Co.; Merck; Novartis; and the Scott R. MacKenzie Foundation 

Disclosure of Relevant Financial Relationships

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

All relevant conflicts of interest have been mitigated prior to the start of the activity.
Efficient LLC and Medical Education Resources' planners and managers have no financial relationships to disclose. 

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Efficient LLC, and/or Mylan Inc., a Viatris Company. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Commercial Support

This activity is supported by educational grant from Mylan Inc., a Viatris Company.

Method of Participation

There are no fees for participating in and receiving credit for this activity. During the period August 21, 2025, through August 21, 2026, participants must: 1) review the learning objectives and faculty disclosures; 2) complete the pre-activity assessment; 3) watch the educational activity and respond to the intra-activity assessments; 4) complete the posttest by recording the best answer to each question; and 5) complete the evaluation form.

Media

Internet

Available Credit

  • 1.00 AAPA Category I CME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Price

Cost:
$0.00
Please login or register to take this course.